Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164818 | 0.90 | MAPT (1.00) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL25227301 | 0.90 | MAPT (1.00) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL30282392 | 0.90 | MAPT (1.00) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL25209200 | 0.90 | MAPT (1.00) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL14990444 | 0.87 | MAPT (0.79) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL20676016 | 0.85 | MAPT (0.77) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL21611288 | 0.85 | MAPT (0.77) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL20676021 | 0.82 | MAPT (0.72) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL11997219 | 0.82 | MAPT (0.72) | MAPTKMT2APOLBALOX15RECQL | |
| SCHEMBL12741627 | 0.82 | MAPT (0.72) | MAPTKMT2APOLBALOX15RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014139979-A1 | QUANTUM DOT IN SITU HYBRIDIZATION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| EP-3099332-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015116774-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-06 | — | — | WO | disclosed |
| EP-2809804-A2 | HYPERTHERMOPHILIC POLYMERASE ENABLED PROXIMITY EXTENSION ASSAY | Olink AB (SE) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013113699-A2 | HYPERTHERMOPHILIC POLYMERASE ENABLED PROXIMITY EXTENSION ASSAY | OLINK AB (SE) | 2013-08-08 | — | — | WO | disclosed |
| EP-1079859-A4 | BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON | UNIV LELAND STANFORD JUNIOR (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1079859-A1 | BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061055-A1 | BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-02 | — | — | WO | disclosed |